Playback speed
10 seconds
ASCO GI 2023 Phase 3 SPOTLIGHT Study Primary Results: Zolbetuximab + mFOLFOX6 as 1L Treatment for Patients With CLDN18.2+/HER2- Locally Advanced Unresectable/Metastatic Gastric or GEJ Adenocarcinoma
By
ASCO GI 2023 Conference Coverage
FEATURING
Kohei Shitara
By
ASCO GI 2023 Conference Coverage
FEATURING
Kohei Shitara
0 views
January 26, 2023
Comments 0
Login to view comments.
Click here to Login